Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA.
Am J Surg Pathol. 2010 Jun;34(6):896-900. doi: 10.1097/PAS.0b013e3181dd60d3.
Myoepithelial cells surrounding spaces involved by ductal carcinoma in situ show phenotypic differences from normal myoepithelial cells. Myoepithelial cells are also present around entrapped glandular spaces in benign sclerosing lesions of the breast, but the immunophenotype of these myoepithelial cells has not been characterized. We evaluated myoepithelial cell immunophenotype in 48 benign sclerosing lesions using antibodies to 7 myoepithelial cell markers (smooth muscle actin, calponin, smooth muscle myosin heavy chain, p63, CD10, cytokeratin 5/6, and p75). Staining intensity of the myoepithelial cells surrounding entrapped glands was compared with that of myoepithelial cells surrounding normal ducts and lobules on the same section. When compared with normal breast ducts and lobules on the same slide, myoepithelial cells associated with benign sclerosing lesions showed reduced expression of cytokeratin 5/6 in 31.8% of cases, smooth muscle myosin heavy chain in 20.9%, CD10 in 15.2%, p63 in 9.3%, and calponin in 6.4%. In 15.9% of cases, myoepithelial cells surrounding entrapped glands showed complete absence of staining for cytokeratin 5/6. None of the cases showed reduced myoepithelial cell expression of smooth muscle actin or p75. The proportion of radial scars/complex sclerosing lesions and sclerosing adenosis with reduced expression was significantly different for CD10 (26.9% and 0% respectively; P=0.01) and p63 (17.4% and 0% respectively; P=0.05). We conclude that myoepithelial cells associated with benign sclerosing lesions of the breast may show immunophenotypic differences from normal myoepithelial cells. This needs to be taken into consideration when selecting myoepithelial markers to help distinguish benign sclerosing lesions from invasive breast cancer.
围绕着导管原位癌的腔隙的肌上皮细胞表现出与正常肌上皮细胞不同的表型。在乳腺良性硬化性病变中也存在围绕着被包裹的腺腔的肌上皮细胞，但这些肌上皮细胞的免疫表型尚未被描述。我们使用 7 种肌上皮细胞标志物（平滑肌肌动蛋白、钙调蛋白、平滑肌肌球蛋白重链、p63、CD10、细胞角蛋白 5/6 和 p75）评估了 48 例良性硬化性病变中的肌上皮细胞免疫表型。比较了与同一切片上正常导管和小叶周围的腺腔相关的肌上皮细胞的染色强度。与同一切片上的正常乳腺小叶和导管相比，与良性硬化性病变相关的肌上皮细胞在 31.8%的病例中显示细胞角蛋白 5/6 表达减少，20.9%的病例中平滑肌肌球蛋白重链表达减少，15.2%的病例中 CD10 表达减少，9.3%的病例中 p63 表达减少，6.4%的病例中钙调蛋白表达减少。在 15.9%的病例中，围绕被包裹的腺腔的肌上皮细胞完全缺乏细胞角蛋白 5/6 的染色。没有病例显示平滑肌肌动蛋白或 p75 的肌上皮细胞表达减少。CD10（分别为 26.9%和 0%；P=0.01）和 p63（分别为 17.4%和 0%；P=0.05）的表达减少在伴有和不伴有 CD10 和 p63 表达减少的放射状瘢痕/复杂硬化性病变和硬化性腺病中的比例差异有统计学意义。我们得出结论，与乳腺良性硬化性病变相关的肌上皮细胞可能表现出与正常肌上皮细胞不同的免疫表型。在选择肌上皮细胞标志物来帮助区分良性硬化性病变和浸润性乳腺癌时，需要考虑这一点。
